Syntara Ltd (SNT) - Total Assets
Based on the latest financial reports, Syntara Ltd (SNT) holds total assets worth AU$21.44 Million AUD (≈ $15.17 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Syntara Ltd net assets for net asset value and shareholders' equity analysis.
Syntara Ltd - Total Assets Trend (2003–2025)
This chart illustrates how Syntara Ltd's total assets have evolved over time, based on quarterly financial data.
Syntara Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Syntara Ltd's total assets of AU$21.44 Million consist of 97.8% current assets and 2.2% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 70.3% |
| Accounts Receivable | AU$5.66 Million | 26.4% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$180.00K | 0.8% |
| Intangible Assets | AU$149.00K | 0.7% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how Syntara Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Syntara Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Syntara Ltd's current assets represent 97.8% of total assets in 2025, an increase from 90.1% in 2003.
- Cash Position: Cash and equivalents constituted 70.3% of total assets in 2025, down from 89.6% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 26.4% of total assets.
Syntara Ltd Competitors by Total Assets
Key competitors of Syntara Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277
|
China | CN¥1.77 Billion |
Syntara Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.93 | 1.79 | 3.59 |
| Quick Ratio | 3.93 | 1.79 | 3.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$15.63 Million | AU$4.32 Million | AU$17.67 Million |
Syntara Ltd - Advanced Valuation Insights
This section examines the relationship between Syntara Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.26 |
| Latest Market Cap to Assets Ratio | 1.45 |
| Asset Growth Rate (YoY) | 106.6% |
| Total Assets | AU$21.44 Million |
| Market Capitalization | $31.20 Million USD |
Valuation Analysis
Above Book Valuation: The market values Syntara Ltd's assets above their book value (1.45x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Syntara Ltd's assets grew by 106.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Syntara Ltd (2003–2025)
The table below shows the annual total assets of Syntara Ltd from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$21.44 Million ≈ $15.17 Million |
+106.56% |
| 2024-06-30 | AU$10.38 Million ≈ $7.35 Million |
-56.79% |
| 2023-06-30 | AU$24.03 Million ≈ $17.00 Million |
-4.61% |
| 2022-06-30 | AU$25.19 Million ≈ $17.82 Million |
-25.02% |
| 2021-06-30 | AU$33.59 Million ≈ $23.77 Million |
-5.16% |
| 2020-06-30 | AU$35.42 Million ≈ $25.06 Million |
-32.76% |
| 2019-06-30 | AU$52.67 Million ≈ $37.27 Million |
+5.13% |
| 2018-06-30 | AU$50.10 Million ≈ $35.45 Million |
+10.26% |
| 2017-06-30 | AU$45.43 Million ≈ $32.15 Million |
-30.80% |
| 2016-06-30 | AU$65.65 Million ≈ $46.45 Million |
-20.48% |
| 2015-06-30 | AU$82.56 Million ≈ $58.42 Million |
+23.69% |
| 2014-06-30 | AU$66.75 Million ≈ $47.23 Million |
-40.55% |
| 2013-06-30 | AU$112.28 Million ≈ $79.45 Million |
-14.75% |
| 2012-06-30 | AU$131.70 Million ≈ $93.19 Million |
+39.26% |
| 2011-06-30 | AU$94.57 Million ≈ $66.92 Million |
-32.82% |
| 2010-06-30 | AU$140.77 Million ≈ $99.60 Million |
-14.16% |
| 2009-06-30 | AU$164.00 Million ≈ $116.04 Million |
+31.15% |
| 2008-06-30 | AU$125.05 Million ≈ $88.48 Million |
+51.30% |
| 2007-06-30 | AU$82.65 Million ≈ $58.48 Million |
-20.73% |
| 2006-06-30 | AU$104.27 Million ≈ $73.78 Million |
+174.84% |
| 2005-06-30 | AU$37.94 Million ≈ $26.84 Million |
+34.24% |
| 2004-06-30 | AU$28.26 Million ≈ $20.00 Million |
-5.15% |
| 2003-06-30 | AU$29.79 Million ≈ $21.08 Million |
-- |
About Syntara Ltd
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more